Thyroid cancer, the most common endocrine malignancy, has seen a dramatic global rise in incidence, surging by over 300% over the past three decades.Critical data for thyroid cancer staging and risk assessment are often buried within lengthy, unstructured clinical notes, making manual extraction laborious and time-consuming—potentially delaying crucial treatment decisions. To address this challenge, an interdisciplinary research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed), the InnoHK Laboratory of Data Discovery for Health (D²4H), and the London School of Hygiene & Tropical Medicine (LSHTM) has developed the world’s first artificial intelligence (AI) model capable of classifying both cancer stage and risk level in thyroid cancer patient with an accuracy exceeding 90%.

Psoriasis is a chronic inflammatory disorder characterized by systemic inflammation and elevated circulating levels of pro-inflammatory cytokines.¹ This persistent inflammatory state has been implicated in immune-mediated injury across multiple organ systems, with particular involvement of renal tissues.¹ However, few large-scale studies have evaluated whether psoriasis independently increases the risk of renal complications in type 2 diabetes mellitus (T2DM) patients receiving guideline-directed renoprotective therapies.² A retrospective cohort study was performed by researchers in Texas to compare the risk of diabetic nephropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis in T2DM patients with and without psoriasis who were receiving angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies.²